Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator: Rachel Applegate
Phone: 713.441.9120
The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG). NCT number: NCT03971422 ... Read more >
Status: Enrolling
Investigator: Jason Thonhoff
Study Coordinator: Rosilyn Gborogen
Phone: 713.441.5192
The purpose of this study is to measure the safety and effectiveness of Spinraza in adults with SMA. ... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator:
Phone:
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG). NCT number: NCT04124965 ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis. NCT Number:NCT03304054 ... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator: Sharon Halton
Phone: 713.441.3420
The primary objective of the study is: • To provide patients with CMS access to amifampridine phosphate therapy until the product becomes commercially available or development is discontinued. The secondary objective of the study is: • ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
Provide natural history data, biomarkers, and biological understanding of the phenotypic heterogeneity of myotonic dystrophy type 1 (DM1). ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
Evaluate the long-term safety of amifampridine phosphate in the symptomatic relief of antibody positive MuSK-MG. NCT Number: NCT03579966 ... Read more >
Status: Open Not Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work eval ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
This is a registry of people with neuromuscular diseases. It is the intent to follow patients with ALS and other neuromuscular diseases to determine best practices for care delivery. ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
This is a Phase III, prospective, multicenter study with two study parts (epochs) to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia (IGI, 10% with recombinant human hyaluronidase (rHuPH20) administered subcutaneously) for maint ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). [NCT03920293] ... Read more >
